Nanobiotix (LTS:0QAV) Total Stockholders Equity: €-84.48 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QAV Nanobiotix SA LTS:0QAV
24 GF Score
Price €37.32
! 3 Warning Signs
View Full Analysis

What is Nanobiotix Total Stockholders Equity?

Nanobiotix LTS:0QAV -3.41% 24 Total Stockholders Equity is €-84.48 Mil as of Dec. 2025. GuruFocus rates LTS:0QAV with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Nanobiotix's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €-84.48 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Nanobiotix's Book Value per Share for the quarter that ended in Dec. 2025 was €-1.75. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Nanobiotix's Debt-to-Equity for the quarter that ended in Dec. 2025 was -1.13.


Nanobiotix  (LTS:0QAV) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Nanobiotix's Book Value per Share for the quarter that ended in Dec. 2025 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Nanobiotix's Debt-to-Equity for the quarter that ended in Dec. 2025 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanobiotix Total Stockholders Equity Related Terms


Nanobiotix Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Nanobiotix's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanobiotix Total Stockholders Equity Chart

Nanobiotix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.79 -27.05 -1.84 -65.70 -84.48

Nanobiotix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.84 -21.78 -65.70 -68.95 -84.48
LTS:0QAV
24GF Score
Nanobiotix SA LTS:0QAV
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €-84.48 Mil mean?
Nanobiotix (LTS:0QAV) has a Total Stockholders Equity of €-84.48 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Nanobiotix and its competitors.
Is Nanobiotix's Total Stockholders Equity too high?
Nanobiotix's current Total Stockholders Equity is €-84.48 Mil. Overall, Nanobiotix has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Nanobiotix's Total Stockholders Equity compare to VRTX and REGN?
Nanobiotix's Total Stockholders Equity of €-84.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Nanobiotix and its competitors. Nanobiotix's current Total Stockholders Equity is €-84.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanobiotix stock overvalued right now?
Nanobiotix (LTS:0QAV) has a current Total Stockholders Equity of €-84.48 Mil. The current Total Stockholders Equity is €-84.48 Mil. Nanobiotix's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Nanobiotix (LTS:0QAV), the current Total Stockholders Equity is €-84.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanobiotix Business Description

Address 60 Rue de Wattignies, Paris, FRA, 75012
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
24GF Score

Get the complete analysis for LTS:0QAV

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.32
Price